Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab

Filing Before Pivotal Data Beats Lilly’s Pre-Phase III Submission

 
• By Mandy Jackson

Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results. 

Pair of aces with poker chips
Time will tell if Eisai and Biogen are holding a pair of aces with Aduhelm and lecanemab • Source: Alamy

More from Neurological

More from Therapy Areas